Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Pfizer to sell $3 billion stake in Sensodyne maker Haleon

Published by Global Banking and Finance Review

Posted on January 14, 2025

Featured image for article about Finance

(Reuters) -Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer healthcare company to about 7.3% from 15%, its bookrunner JPMorgan said on Wednesday.

The sale of 700 million Haleon shares at 357 pence apiece is a discount of about 2.8% to the stock's closing price on Tuesday.

Shares in the maker of Sensodyne, Panadol and Advil, which gained 17% in 2024, were up 0.7% at 369.7 pence in morning trade on Wednesday, in line with the broader FTSE 100.

The sale represents nearly 7.7% of the issued share capital of Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019. It was spun off from the British drugmaker in 2022.

Pfizer, which will remain Haleon's largest shareholder after the sale, said in 2023 it would cut its ownership in a "slow and methodical" manner within months.

The U.S. drugmaker is under pressure from hedge fund Starboard Value to hold its management accountable for underperformance. Last October it sold a $3.3 billion stake in Haleon, while GSK sold its entire stake in May.

JPMorgan and Morgan Stanley are joint global coordinators and joint bookrunners for the share sale.

In October Haleon missed third-quarter forecasts, hurt by a stronger pound and lower sales of its painkiller Panadol in Australia and the Middle East.

($1 = 0.8199 pounds)

(Reporting by Aatrayee Chatterjee and Anandita Mehrotra in Bengaluru; Editing by Shailesh Kuber, Arun Koyyur and Jan Harvey)